SAN DIEGO, March 22, 2022 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the Phase 3, RESUME-1, clinical study of tolperisone for the relief of muscle spasm associated with acute, painful musculoskeletal conditions, failed to meet its primary and key secondary endpoints.
Neurana Pharmaceuticals has concluded subject enrolment in a Phase III nRESUME-1 clinical trial of its therapy, tolperisone, to treat muscle nspasms linked to acute, painful musculoskeletal conditions.
SAN DIEGO, Nov. 29, 2021n/PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company nfocused on the treatment of neuromuscular conditions, today announced itnhas completed enrollment of its 1,000 patient Phase 3 RESUME-1 Study ofntolperisone for the relief of muscle spasm associated with acute, npainful musculoskeletal conditions. Neurana anticipates reporting ntopline data in the first quarter of 2022.
SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the Wells Fargo Virtual Healthcare Conference and participate in one-on-one meetings with investors. The conference takes place September 9th–10th. Presentations will be available for registered attendees via the Wells Fargo conference site.
SAN DIEGO, Calif., Aug. 30, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the presentation of scientific abstracts at two congresses, the 28th Annual Napa Pain Conference August 27-28th, 2021, and PAIN Week September 7-11th, 2021.
Neurana Pharmaceuticals to Participate at the SVB Leerink Conference
Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced participation at the William Blair Biotech Focus Conference. The conference takes place virtually July 14-15th. Presentations will be available for registered attendees via the William Blair conference site.
SAN DIEGO, June 7, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000 subjects have been enrolled in the Phase 3, RESUME-1 clinical study of tolperisone, a novel, non-opioid, centrally acting muscle relaxant in clinical development for the treatment of symptoms associated with acute and painful muscles spasms of the back.
SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the Piper Sandler 32nd Annual Healthcare Conference and participate in one-on-one meetings with investors. The conference takes place virtually November 30th to December 3rd. Presentations will be available for registered attendees via the Piper Sandler conference site.
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology company focused on the treatment of neuromuscular conditions, today announced the publication of results from the dose-ranging Phase 2 STAR Study of tolperisone in patients with acute and painful muscle spasms of the lower back, in the Journal of Pain Research.